if dal is dead, is CV franchise too?

Quote






Dal isn't dead. We hear the voices telling us to plan on being called back to launch it! As long as no one checks our horrible HR records, our consistently poor sales performances, our lack of ability to communicate with our reps. and show leadership, our total lack of respect for others and those unfortunate intervention meetings we had to have with upper management and our divisions to straighten us out.

Sincerely,
Two Psychotic Female Managers in Florida waiting next to the phone for the call
 






CV, lytics, vascular medicine - whatever you want to call this franchise, the death of dal is the final nail in the coffin. If you can, try to transfer to another franchise (good luck with that). Otherwise, update your resume, and start the job hunt now while you still have a paycheck.
 






Anonymous said:
CV, lytics, vascular medicine - whatever you want to call this franchise, the death of dal is the final nail in the coffin. If you can, try to transfer to another franchise (good luck with that). Otherwise, update your resume, and start the job hunt now while you still have a paycheck.
Click to expand...

Genentech dont kid yourself. taspo and dal were the future of the company. The sales of those two products alone were going to support all kinds of future projects and sales reps for years to come. Things are not ok in genentech land.
 






Anonymous said:
Genentech dont kid yourself. taspo and dal were the future of the company. The sales of those two products alone were going to support all kinds of future projects and sales reps for years to come. Things are not ok in genentech land.
Click to expand...

Wrong. taspo and dal were the future of Roche primary care. Gene meds are all biologics that don't look to have generic competition anytime soon
 












The issue isn't biosimilars. It's all about the bottom line: how much profit will the CV brands generate with a promotional sales force vs without one. The ROI lines have been dangerously close over the past few years, but dal was used as leverage to keep the franchise alive. Now that dal is dead, CV's days are numbered. It's been a great ride, but most of us knew it would end someday. If you are in CV, network with those that have left for newer ventures. You may be needing a interview sooner than you think.
 






Anonymous said:
Wrong. taspo and dal were the future of Roche primary care. Gene meds are all biologics that don't look to have generic competition anytime soon
Click to expand...

Wrong buddy, dal and taspo were absolutely supposed to be a major part of the growth of Roche, at 8-10 billion per year peak. You are still stupidly trying to split genentech into old and new. GNE is dead, it is now roche, there are NOT two separate companies. For crying out loud this has been a dead horse for four years.

You need to go to business school. Its not about selling 10b of avastin every year, its about growth! If you sell 10b today, investors want 12 b tomorrow. So, yes Roche has successful cancer drugs etc, but they are not growing. You need competitive new products (aka pipeline) to fuel growth; that what taspo and dal were supposed to do. Their demise is a big, big, deal. What is avasting doing vs last year, what is herceptin doing vs last year, what about lucentis? Thats is what makes your company valuable, not the absolute dollar. By the way, havent you heard of biosimilars? People will be lining up to create kockoffs of these products when they are off patents.

Again, I suggest you go to business school, to get a little commercial awareness.
 






Genentech Diabetes is Dead

Not only are Taspoglutide (a biologic) and Dalcetrapib dead, but word on the street is that RG7685 the GLP-1/GIP dual agonist peptide analogue is about to be killed too. Note that the company is not participating in the Amylin auction either...

Move into another sales force or go get a job with Arena or Vivus
 
























Top Bottom
Back
Quote